Report : Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)
At 3.3% CAGR, the MEA Human Papillomavirus (HPV) Vaccine Market is speculated to be worth US$ 100.86 million by 2028, says The Insight Partners
According to Business Market Insights’ research, the MEA human papillomavirus (HPV) vaccine market was valued at US$ 82.91 million in 2022 and is expected to reach US$ 100.86 million by 2028, registering an annual growth rate of 3.3% from 2022 to 2028. The advancements in HPV diagnostics tests and initiatives taken by health organizations are the critical factors attributed to the market expansion.
Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers -- p16 and Ki-67 in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers is more significantly at risk for disease. Such robust developments in HPV diagnostics tests are likely to reshape the HPV vaccines market during the forecast period.
On the contrary, high cost of HPV vaccines hurdles the growth of MEA human papillomavirus (HPV) vaccine market.
Based on type, the MEA human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 58.5% market share in 2022, amassing US$ 48.54 million. It is projected to garner US$ 59.96 million by 2028 to expand at 3.6% CAGR during 2022–2028.
Based on dosage, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 85.9% market share in 2022, amassing US$ 71.25 million. It is projected to garner US$ 87.00 million by 2028 to expand at 3.4% CAGR during 2022–2028.
Based on age, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 82.3% market share in 2022, amassing US$ 68.27 million. It is projected to garner US$ 83.67 million by 2028 to expand at 3.4% CAGR during 2022–2028.
Based on application, the MEA human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 88.1% market share in 2022, amassing US$ 73.01 million. It is projected to garner US$ 89.64 million by 2028 to expand at 3.5% CAGR during 2022–2028.
Based on end user, the MEA human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 31.5% market share in 2022, amassing US$ 26.10 million. It is projected to garner US$ 30.99 million by 2028 to expand at 2.9% CAGR during 2022–2028.
Based on country, the MEA human papillomavirus (HPV) vaccine market has been categorized into Saudi Arabia, South Africa, the UAE, Iran, Turkey, Kuwait, Bahrain, Egypt, and rest of MEA. Our regional analysis states that Saudi Arabia captured 29.6% market share in 2022. It was assessed at US$ 24.57 million in 2022 and is likely to hit US$ 29.52 million by 2028, exhibiting a CAGR of 3.1% during the forecast period.
Key players dominating the MEA human papillomavirus (HPV) vaccine market are GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; and Walvax Biotechnology Co., Ltd. among others.
- In May 2022, Serum Institute of India is developing a tetravalent HPV vaccine which includes L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of approximately 90% against papilloma virus prevalent in the developing world. The vaccine is currently under development and will be available in the near future.
- In March 2021, INOVIO announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA 5PSP device.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: email@example.com